127 related articles for article (PubMed ID: 20151336)
1. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.
Guo D; Myrdal PB; Karlage KL; O'Connell SP; Wissinger TJ; Tabibi SE; Yalkowsky SH
AAPS PharmSciTech; 2010 Mar; 11(1):247-52. PubMed ID: 20151336
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
4. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
[TBL] [Abstract][Full Text] [Related]
5. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
Xiang TX; Niemi R; Bummer P; Anderson BD
J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
[TBL] [Abstract][Full Text] [Related]
6. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
7. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
Newman EM; Morgan RJ; Kummar S; Beumer JH; Blanchard MS; Ruel C; El-Khoueiry AB; Carroll MI; Hou JM; Li C; Lenz HJ; Eiseman JL; Doroshow JH
Cancer Chemother Pharmacol; 2015 Mar; 75(3):537-46. PubMed ID: 25567350
[TBL] [Abstract][Full Text] [Related]
8. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
9. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Parise RA; Egorin MJ; Eiseman JL; Joseph E; Covey JM; Beumer JH
Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
[TBL] [Abstract][Full Text] [Related]
10. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.
Holleran JL; Eiseman JL; Parise RA; Kummar S; Beumer JH
J Pharm Biomed Anal; 2016 Sep; 129():359-366. PubMed ID: 27454087
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution, Tumor Detection, and Radiation Dosimetry of
Young CR; Adler S; Eary JF; Lindenberg ML; Jacobs PM; Collins J; Kummar S; Kurdziel KA; Choyke PL; Mena E
J Nucl Med; 2019 Apr; 60(4):492-496. PubMed ID: 30389817
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and mechanism of action of 5-fluorodeoxycytidine.
Newman EM; Santi DV
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6419-23. PubMed ID: 6959127
[TBL] [Abstract][Full Text] [Related]
14. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
15. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne GO'; Wang L; Zlott J; Juwara L; Covey JM; Beumer JH; Cristea MC; Newman EM; Koehler S; Nieva JJ; Garcia AA; Gandara DR; Miller B; Khin S; Miller SB; Steinberg SM; Rubinstein L; Parchment RE; Kinders RJ; Piekarz RL; Kummar S; Chen AP; Doroshow JH
Cancer Chemother Pharmacol; 2020 May; 85(5):979-993. PubMed ID: 32314030
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
[TBL] [Abstract][Full Text] [Related]
17. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
[TBL] [Abstract][Full Text] [Related]
18. Reversal of deamination-related cytotoxicity of 5-methyl-2'-deoxycytidine by tetrahydrouridine in human leukemia cells.
Jekunen A; Vilpo JA
J Natl Cancer Inst; 1984 Nov; 73(5):1087-91. PubMed ID: 6593484
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydrouridine specifically facilitates deoxycytidine incorporation into herpes simplex virus DNA.
North TW; Mathews CK
J Virol; 1981 Mar; 37(3):987-93. PubMed ID: 6262539
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
